» Articles » PMID: 28427079

Diagnostic Accuracy of Combinations of Tumor Markers for Malignant Pleural Effusion: An Updated Meta-Analysis

Overview
Journal Respiration
Publisher Karger
Specialty Pulmonary Medicine
Date 2017 Apr 21
PMID 28427079
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The role of combinations of tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125, 15-3, and 19-9, and CYFRA 21-1 (a fragment of cytokeratin 19) in diagnosing malignant pleural effusion (MPE) has not been clearly established.

Objectives: This meta-analysis was performed to establish the overall diagnostic accuracies of combinations of these pleural fluid tumor markers for MPE.

Methods: The PubMed, Ovid, Embase, Web of Science, and Cochrane bibliographic databases were searched. Sensitivity, specificity, and other measures of the accuracy of combinations of pleural CEA, CA 125, CA 15-3, CA 19-9, and CYFRA 21-1 in the diagnosis of MPE were pooled after a systematic review of English-language studies.

Results: Twenty studies met the inclusion criteria. For pleural fluid tumor marker combinations including more than 3 studies, the summary estimates of the sensitivity/specificity for diagnosing MPE were as follows: CEA + CA 125, 0.65/0.98; CEA + CA 15-3, 0.64/0.98; CEA + CA 19-9, 0.58/0.98; CEA + CYFRA 21-1, 0.82/0.92; and CA 15-3 + CYFRA 21-1, 0.88/0.94.

Conclusions: In patients with undiagnosed pleural effusion, the combinations of positive pleural CEA + CA 15-3 and CEA + CA 19-9 are highly suspicious for pleural malignancy, but the sensitivity of these tests is poor. Therefore, their routine role in the diagnostic algorithm of these patients is questionable, and management decisions should depend on positive cytological or biopsy results from the pleura.

Citing Articles

Tumor Markers in Pleural Fluid: A Comprehensive Study on Diagnostic Accuracy.

Aleksiev V, Markov D, Bechev K Diagnostics (Basel). 2025; 15(2).

PMID: 39857088 PMC: 11765104. DOI: 10.3390/diagnostics15020204.


Malignant pleural disease.

Piggott L, Hayes C, Greene J, Fitzgerald D Breathe (Sheff). 2024; 19(4):230145.

PMID: 38351947 PMC: 10862126. DOI: 10.1183/20734735.0145-2023.


Pleural fluid carbohydrate antigen 72-4 and malignant pleural effusion: a diagnostic test accuracy study.

Cao X, Yan L, Jiang T, Huang J, Chen H, Porcel J Ther Adv Respir Dis. 2024; 18:17534666231222333.

PMID: 38189269 PMC: 10775747. DOI: 10.1177/17534666231222333.


A simple and efficient clinical prediction scoring system to identify malignant pleural effusion.

Wang S, An J, Hu X, Zeng T, Li P, Qin J Ther Adv Respir Dis. 2024; 18:17534666231223002.

PMID: 38189181 PMC: 10775726. DOI: 10.1177/17534666231223002.


Development and validation of a machine learning model for differential diagnosis of malignant pleural effusion using routine laboratory data.

Wei T, Zhang J, Cheng Z, Jiang L, Li J, Zhou L Ther Adv Respir Dis. 2023; 17:17534666231208632.

PMID: 37941347 PMC: 10637149. DOI: 10.1177/17534666231208632.